All News
JAKi in inflammatory myositis?
Abstract 1731 is a small RCT of baricitinib in inflammatory myositis comparing early start baricitinib to later start.
Read Article
My ramblings on the SELECT-GCA study and predictions of the place of upadacitinib in clinical practice in GCA are up now on RheumNow #ACR24 @RheumNow https://t.co/DR5VgVmdse
Richard Conway RichardPAConway ( View Tweet)
I've shared some further thoughts on @jeffsparks SAIL-RA study and its finding of the strong association of RA-ILD with disease activity in early RA. And of course couldn't resist going on a tangent about the ACR ILD guidelines! #ACR24 @RheumNow https://t.co/UUDbWw38Im
Richard Conway RichardPAConway ( View Tweet)
A key practice changing study (I hope) from #ACR24 has been the preCARA study. Fertility increases with aggressive disease control. My video on this study is up now on @RheumNow https://t.co/Pf3rdTHbOJ
Richard Conway RichardPAConway ( View Tweet)
The TAPIR study presented at #ACR24 may not be as attention grabbing as others like SELECT-GCA, but in my opinion it is arguablyone of the most important ANCA-vasculitis studies ever. I've shared some further thoughs in an article on @RheumNow https://t.co/mImAE8ezSQ
Richard Conway RichardPAConway ( View Tweet)
RheumNow Day 2 Recap: ACR Convergence 2024 Highlights https://t.co/YAwOEaNsWs
Links:
Dr. John Cush RheumNow ( View Tweet)
RheumNow’s expanded coverage of the #ACR24 Annual meeting is sponsored in part by Novartis. All content is chosen by RheumNow & its faculty
Dr. John Cush RheumNow ( View Tweet)
We saw evidence for JAK use in GCA this conference... what about IL-1 inhibition?
Double-blind RCT: Anakinra vs. PBO w/ similar GC taper in GCA pt
NO difference in relapse rate at 26, 52 wks despite addition of Anakinra
@RheumNow #ACR24 Abst1699 https://t.co/gUb0gGJjTG
Brian Jaros, MD Dr_Brian_MD ( View Tweet)
VERY exciting SLE update from Fava et al. Machine learning used to generate urinary protein panel predictive of intra-renal inflammation BETTER than serum biomarkers C3, C4, dsDNA Also monitoring tool for renal response. Outstanding. @RheumNow #ACRbest #ACR24 https://t.co/YXgKrSU4UQ
Links:
Brian Jaros, MD Dr_Brian_MD ( View Tweet)
To stop tsDMARD / bDMARD To improve #COVIDVACCINE response in those w several previous #COVID19 #vaccinations is NOT necessary
This will change my practice!
#ACR24 @RheumNow @ACRheum https://t.co/WXeqMOEfuA
Janet Pope Janetbirdope ( View Tweet)
What a result!!!
Crowed split 49% against and 51% for MCTD as a unique disease entity
Given pre-debate poll of >70% for MCTD, looks like an overall win for the “NOT” group
Fantastic session from all the presenters
@RheumNow #ACR24 https://t.co/GgTVQ1VNWP
Brian Jaros, MD Dr_Brian_MD ( View Tweet)
Super helpful results from COVER study, holding JAK or IL17 for COVID boosters Antibody titers went up regardless of holding Holding caused flares (14-25% increase!) Pretty clear message; continue JAK / IL17 #ACR24 @RheumNow Abstr#1718 #ACRbest https://t.co/Mf89dWrRWz
Mike Putman EBRheum ( View Tweet)
Would be helpful for us (and pts) to better understand rimmunotherapy agent specific risk on subsequent GCA/PMR
AFTRER propensity matching of >7k pt on combo nivolumab/ipilimumab compared to pembrolizumab:
- PMR RR 3.8x N/I vs. P
- no diff in GCA risk
@RheumNow #ACR24 https://t.co/IF4Gh7Cumd
Brian Jaros, MD Dr_Brian_MD ( View Tweet)
🔶Clinical Year in Review #ACR24 🔶
Talk By @MHPillingerMD
• Review some of the most impactful studies in Rheumatology from the past year!
#RheumTwitter #Rheumatology https://t.co/1ULDB2l4gX
Mithu Maheswaranathan, MD MithuRheum ( View Tweet)
The anti-MCTD group strikes back
Of cohort of over 1,000 RNP+ pt, only 17 clinically diagnosed with MCTD
Majority of patients, despite potential overlap, treated for other primary rheum dz
@RheumNow #ACR24 https://t.co/vkQ6UPs34y
Brian Jaros, MD Dr_Brian_MD ( View Tweet)
Older RA patients in RISE with high disease activity show a higher incidence of hip and major osteoporotic fractures. Practice T2T and monitor bone health closely!
#ACR24 @RheumNow ABST#1748 https://t.co/7MCAIrfXhp
Jiha Lee JihaRheum ( View Tweet)
Phase 2 RCT of MK2 inhibitor did not show clinical efficacy at week 12 in active AS pts compared to PBO.
There are still unmet needs for additional therapeutics in pts with AS that not respond to current therapies.
Abst#1760 #ACR24 @RheumNow https://t.co/cXv8HYr0Xr
Links:
Adela Castro AdelaCastro222 ( View Tweet)
Comparison of infection risk across b/tsDMARDs in IA in real-world study
Treatment with
➡️Rituximab
➡️JAKi
➡️Anti-IL6
assoc with ⬆️⬆️ risk of severe infection compared to TNFi
A reminder to consider comorbidities & infection risk in selecting b/tsDMARDs
Ab1716 #ACR24 @RheumNow
Mrinalini Dey DrMiniDey ( View Tweet)
RCTs are the gold standard in drug research, but rising placebo (PBO) response rates with global recruitment could distort treatment effects. Limited access to care in less affluent countries may be a factor.
#ACR24 @RheumNow ABST#1746 https://t.co/fVeNcw5qwO
Jiha Lee JihaRheum ( View Tweet)
SURPASS trial of bio naïve axSpA at risk of radiographic progression:
1. Presence of syndesmophytes
2. Higher CRP levels
3. Higher ASDAS
4. Higher spinal MRI BME scores
Were predictors of spinal progression independent of ttnt
Abst#1759 #ACR24 @RheumNow https://t.co/QC9FMPufPY
Links:
Adela Castro AdelaCastro222 ( View Tweet)